251 related articles for article (PubMed ID: 26389554)
1. Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism.
Kharasch ED; Regina KJ; Blood J; Friedel C
Anesthesiology; 2015 Nov; 123(5):1142-53. PubMed ID: 26389554
[TBL] [Abstract][Full Text] [Related]
2. Methadone pharmacogenetics in vitro and in vivo: Metabolism by CYP2B6 polymorphic variants and genetic variability in paediatric disposition.
Wang PF; Sharma A; Montana M; Neiner A; Juriga L; Reddy KN; Tallchief D; Blood J; Kharasch ED
Br J Clin Pharmacol; 2022 Nov; 88(11):4881-4893. PubMed ID: 35538637
[TBL] [Abstract][Full Text] [Related]
3. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment.
Crettol S; Déglon JJ; Besson J; Croquette-Krokkar M; Gothuey I; Hämmig R; Monnat M; Hüttemann H; Baumann P; Eap CB
Clin Pharmacol Ther; 2005 Dec; 78(6):593-604. PubMed ID: 16338275
[TBL] [Abstract][Full Text] [Related]
4. Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study.
Dobrinas M; Crettol S; Oneda B; Lahyani R; Rotger M; Choong E; Lubomirov R; Csajka C; Eap CB
Pharmacogenet Genomics; 2013 Feb; 23(2):84-93. PubMed ID: 23249875
[TBL] [Abstract][Full Text] [Related]
5. Role of Cytochrome P4502B6 Polymorphisms in Ketamine Metabolism and Clearance.
Rao LK; Flaker AM; Friedel CC; Kharasch ED
Anesthesiology; 2016 Dec; 125(6):1103-1112. PubMed ID: 27763887
[TBL] [Abstract][Full Text] [Related]
6. Role of cytochrome P4502B6 in methadone metabolism and clearance.
Kharasch ED; Stubbert K
J Clin Pharmacol; 2013 Mar; 53(3):305-13. PubMed ID: 23361846
[TBL] [Abstract][Full Text] [Related]
7. Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics.
Ahmad T; Valentovic MA; Rankin GO
Biochem Pharmacol; 2018 Jul; 153():196-204. PubMed ID: 29458047
[TBL] [Abstract][Full Text] [Related]
8. Differences in Methadone Metabolism by CYP2B6 Variants.
Gadel S; Friedel C; Kharasch ED
Drug Metab Dispos; 2015 Jul; 43(7):994-1001. PubMed ID: 25897175
[TBL] [Abstract][Full Text] [Related]
9. CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone S-enantiomer.
Wang SC; Ho IK; Tsou HH; Tian JN; Hsiao CF; Chen CH; Tan HK; Lin L; Wu CS; Su LW; Huang CL; Yang YH; Liu ML; Lin KM; Chen CY; Liu SC; Wu HY; Chan HW; Tsai MH; Lin PS; Liu YL
J Clin Psychopharmacol; 2011 Aug; 31(4):463-9. PubMed ID: 21694616
[TBL] [Abstract][Full Text] [Related]
10. Novel associations between
Packiasabapathy S; Aruldhas BW; Zhang P; Overholser BR; Quinney SK; Sadhasivam S
Pharmacogenomics; 2021 Jul; 22(10):591-602. PubMed ID: 34100292
[No Abstract] [Full Text] [Related]
11. CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction.
Levran O; Peles E; Hamon S; Randesi M; Adelson M; Kreek MJ
Addict Biol; 2013 Jul; 18(4):709-16. PubMed ID: 21790905
[TBL] [Abstract][Full Text] [Related]
12. Current Concepts in Methadone Metabolism and Transport.
Kharasch ED
Clin Pharmacol Drug Dev; 2017 Mar; 6(2):125-134. PubMed ID: 28263461
[TBL] [Abstract][Full Text] [Related]
13. Impact of ABCB1 and CYP2B6 genetic polymorphisms on methadone metabolism, dose and treatment response in patients with opioid addiction: a systematic review and meta-analysis.
Dennis BB; Bawor M; Thabane L; Sohani Z; Samaan Z
PLoS One; 2014; 9(1):e86114. PubMed ID: 24489693
[TBL] [Abstract][Full Text] [Related]
14. Combined Effect of CYP2B6 Genotype and Other Candidate Genes on a Steady-State Serum Concentration of Methadone in Opioid Maintenance Treatment.
Kringen MK; Chalabianloo F; Bernard JP; Bramness JG; Molden E; Høiseth G
Ther Drug Monit; 2017 Oct; 39(5):550-555. PubMed ID: 28723731
[TBL] [Abstract][Full Text] [Related]
15. Relationship between CYP2B6*6 and cold pressor pain sensitivity in opioid dependent patients on methadone maintenance therapy (MMT).
Zahari Z; Lee CS; Ibrahim MA; Musa N; Mohd Yasin MA; Lee YY; Tan SC; Mohamad N; Ismail R
Drug Alcohol Depend; 2016 Aug; 165():143-50. PubMed ID: 27289271
[TBL] [Abstract][Full Text] [Related]
16. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone.
Kharasch ED; Hoffer C; Whittington D; Sheffels P
Clin Pharmacol Ther; 2004 Sep; 76(3):250-69. PubMed ID: 15371986
[TBL] [Abstract][Full Text] [Related]
17. Tell-Tale SNPs: The Role of CYP2B6 in Methadone Fatalities.
Ahmad T; Sabet S; Primerano DA; Richards-Waugh LL; Rankin GO
J Anal Toxicol; 2017 May; 41(4):325-333. PubMed ID: 28184434
[TBL] [Abstract][Full Text] [Related]
18. Methadone N-demethylation by the common CYP2B6 allelic variant CYP2B6.6.
Gadel S; Crafford A; Regina K; Kharasch ED
Drug Metab Dispos; 2013 Apr; 41(4):709-13. PubMed ID: 23298862
[TBL] [Abstract][Full Text] [Related]
19. Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers.
Eap CB; Crettol S; Rougier JS; Schläpfer J; Sintra Grilo L; Déglon JJ; Besson J; Croquette-Krokar M; Carrupt PA; Abriel H
Clin Pharmacol Ther; 2007 May; 81(5):719-28. PubMed ID: 17329992
[TBL] [Abstract][Full Text] [Related]
20. Toward precision prescribing for methadone: Determinants of methadone deposition.
Talal AH; Ding Y; Venuto CS; Chakan LM; McLeod A; Dharia A; Morse GD; Brown LS; Markatou M; Kharasch ED
PLoS One; 2020; 15(4):e0231467. PubMed ID: 32302325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
